Stay updated with breaking news from Ryan Sullivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An mRNA vaccine from Moderna shows promise at preventing recurrences of melanoma skin cancer, which could mark a turnaround for cancer vaccines.
Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return
A phase two clinical trial found the shot combined with immunotherapy drug Merck slashed the risk of melanoma returning by 44 percent compared to using the drug alone.
For decades, cancer vaccines have been tested, though no real promising results have emerged. However, results of a new clinical trial involving melanoma patients are giving experts a fresh boost of optimism.
The mRNA cancer vaccine combined with immunotherapy improved survival rates for stage 3 and 4 melanoma, Moderna and Merck announced. Here's what to know.